Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Glioblastoma 6Fallopian Tube Neoplasms 6Breast Neoplasms 6Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Renal Cell 4Brain Neoplasms 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Rectal Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1

Interventions

Topotecan 10Etoposide 7Specimen Handling 6berzosertib 5Cisplatin 5Biopsy 5sargramostim 4Platinum 4Magnetic Resonance Spectroscopy 4Irinotecan 4Carboplatin 4trioctyl phosphine oxide 3X-Rays 3Paclitaxel 3Nivolumab 31,2-diaminocyclohexaneplatinum II citrate 3veliparib 2romidepsin 2olaparib 2cabozantinib 2aldesleukin 2Tomography, X-Ray Computed 2Temozolomide 2Sunitinib 2PM 01183 2Electrocardiography 2Depsipeptides 2Decitabine 2Cyclophosphamide 2Budesonide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Small Cell Lung Carcinoma × cediranib × Clear all
NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡